Lepidic component identifies a subgroup of lung adenocarcinoma with a distinctive prognosis: a multicenter propensity-matched analysis.

Erjia ZhuChenyang DaiHuikang XieHang SuXuefei HuMing LiJunqiang FanJinshi LiuQuan ZhuLei ZhangHonggang KeChang Chen

Published in: Therapeutic advances in medical oncology (2020)

Lepidic component presence identifies a LUAD subgroup with an excellent prognosis independent of the LR, pathological T classification. Considering the lepidic component presence may improve prognostic predictions for patients with LUAD.

Keyphrases

genome wide
machine learning
deep learning
phase iii
randomized controlled trial
gene expression
double blind